Lucid Diagnostics Investor Day, December 13, 2023
Fireside Chat with Lucid Executive Leaders - Suman Verma, MD, PhD, Deepika Lakhani, PhD, Victoria Lee, MD, Natalie Carfora
Dr. Suman Verma is Senior Vice President & Chief Scientific Officer of Lucid Diagnostics and oversees research, development, and analytic validation work on the EsoGuard® Esophageal DNA Test at Lucid’s CLIA-certified, CAP-accredited laboratory in Lake Forest, CA. Dr. Verma has more than a decade of experience in the development and implementation of molecular diagnostic assays using the full spectrum of cutting edge molecular biologic techniques and technologies. Dr. Verma earned her Ph.D. and completed a post-doctoral fellowship at the University of California Irvine, during which she performed and published on important research in breast cancer biology and targets for therapeutic intervention in breast cancer. Dr. Verma earned her medical degree, completed her internal medicine training, and served as a staff physician active in clinical research in India.
Deepika Lakhani is Senior Vice President and Chief Regulatory and Quality Officer of Lucid Diagnostics. She is an internationally recognized regulatory professional, with over fifteen years of experience, and has received many awards for excellence and leadership. She spent over a decade at the Food and Drug Administration (FDA), including at both the Center for Drugs Evaluation and Research at the FDA and Center for Devices and Radiological Health, where she reviewed, led cross-disciplinary teams, and contributed to policies impacting drugs, biologics, medical devices, tobacco products and combination products. On the industry side, she has led efforts for global regulatory approvals of drugs, medical devices, combination products and emerging technologies, including at AstraZeneca and as a consultant for Johnson and Johnson. She received her bachelor’s degree in Delhi, India and her PhD Virginia Commonwealth University.
Dr. Victoria Lee is Senior Vice President & Chief Medical Officer of Lucid Diagnostics and its parent company, PAVmed Inc. Dr. Lee bring extensive experience in clinical affairs and research in the medical technology industry, including in pre-market and post-market clinical trials, collaboration with clinical research organizations and key opinion leaders and general oversight of clinical research operations. She has been a frequent collaborator on regulatory submissions to the FDA and European regulatory authorities. She previously served as a physician consultant at McKinsey and Company with a focus on medical policy, resource utilization, and optimizing efficiencies in healthcare. Dr. Lee is a graduate of the University of Washington and NYU Grossman School of Medicine, and completed her training at Harvard and NYU teaching hospitals.
Natalie Carfora is Vice President, Market Access of Lucid Diagnostics. Ms. Carfora brings over a decade of market access and sales experience across diagnostic, medical device & pharmaceutical industries, including successfully engaging with commercial and governmental payors on coverage policy. She most recently served as Head of Market Access of an innovative molecular diagnostic company focused on commercializing a blood-based test for pancreatic cancer. She previously held market access and commercial roles at Myriad Genetics and Eli Lilly. In these roles, Ms. Carfora successfully led and supported a variety of market access initiatives, including collaborating with clinical research teams on study design, driving pilot programs with payors and self-funded clients, as well as utilizing clinical utility studies to inform broader coverage policies. She is an honors graduate of the Questrom School of Business at Boston University.